ClinicalTrials.gg
CompletedNCT01575925POM RenalUpdated Nov 4, 2022

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

A Phase 1 interventional study of 4 mg Oral POM + 40 mg Oral DEX and 2 mg Oral POM + 40 mg Oral DEX in Multiple Myeloma and Renal Impairment, sponsored by Celgene. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-04.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
260th of 373
25 · median 45
Started
2012
with 13 others
Phase 1
42 of 381
5 open now
Registered
132nd of 381
by date
Lead sponsor
12 of 381
Celgene

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 260th largest by enrollment of the 373 interventional ones that give a count, is one of 14 that started in 2012, is one of 42 in phase 1, and was the 132nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and impaired renal function.

Read the detailed description

The primary objective of the study is to determine the PK and safety for the combination of POM + (LD-DEX) in subjects with RRMM and impaired renal function.

The secondary objective of the study is to evaluate the efficacy of POM + (LD_DEX) in subjects with RRMM and impaired renal function.

This is a 3+3 dose escalation design, with one cohort each for patients with severely impaired renal function patients (CrCl \< 30 mL/min) requiring and not requiring dialysis respectively. There will also be one control cohort with normal renal function, these patients will receive 4 mg POM. Dosing will be 21 days out of a 28 day cycle.

03

Conditions studied

  • Multiple Myeloma
  • Renal Impairment

Keywords

  • Pomalidomide for multiple myeloma
  • renal impairment
  • multiple myeloma patients with renal impairment
  • Pomalidomide for patients with renal impairment due to multiple myeloma
  • Pomalidomide
  • dexamethasone
  • RRMM
  • impaired renal function in multiple myeloma
  • hemodialysis
  • dialysis
  • POM
  • Pomalyst
  • MM
  • severe renal impairment
  • CrCl ≤ 30 mL/min
  • Creatinine less than 30
  • clinical trial in subjects with multiple myeloma with renal impairement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Must be ≥ 18 years at the time of signing the form
  2. Must understand and voluntarily sign an informed consent document prior to any study-related assessments/procedures
  3. Must be able to adhere to the study visit schedule and other protocol requirements
  4. Must have documented diagnosis of multiple myeloma and have (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24 hours)
  5. Must have had at least 1 prior anti-myeloma regimen
  6. Must have documented progression as per the International Myeloma Working Group uniform response criteria (Durie, 2006) during or after the last anti-myeloma regimen
  7. (ECOG) performance status score of 0, 1, or 2
  8. Females of (FCBP) must agree to utilize two reliable forms of simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation, and must agree to regular pregnancy testing during this timeframe
  9. Females must agree to abstain from breastfeeding during study participation and for 28 following discontinuation from study treatment
  10. Males must agree to use a latex condom during any sexual contact with FCBP while participating in the study and for 28 days following discontinuation from study treatment, even if he has undergone a successful vasectomy
  11. Males must also agree to refrain from donating semen or sperm while on pomalidomide and for 28 days after discontinuation from study treatment
  12. All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from study treatment
  13. All subjects must agree not to share medication

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Peripheral neuropathy ≥ Grade 2
  2. Non-secretory multiple myeloma
  3. Any of the following laboratory abnormalities:

    • (ANC) \< 1,000/µL
    • count \< 75,000/µL
    • Corrected serum calcium > 14 mg/dL (> 3.5 mmol/L)
    • \< 8 g/dL (\< 4.9 mmol/L; prior RBC transfusion or recombinant human erythropoietin use is permitted)
    • Serum glutamic oxaloacetic transaminase/ (SGOT/AST) or serum glutamic pyruvic transaminase/alanine aminotransferase (SGPT/ALT) > 3.0 x (ULN)
    • Serum total > 2.0 mg/dL
  4. Prior history of , other than the disease being studied, unless the subject has been free of the malignancy for ≥ 5 years from initiating study treatment, with the following exceptions:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, ] clinical staging system).
  5. Previous therapy with Pomalidomide
  6. to thalidomide, lenalidomide, or dexamethasone
  7. Rash ≥ Grade 3 during prior thalidomide or lenalidomide therapy
  8. Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide
  9. Subjects with any one of the following:

    • Congestive heart failure ( Class III or IV)
    • Myocardial infarction within 12 months prior to starting study treatment
    • Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris
  10. Subjects who received any of the following within the last 14 days of initiation of study treatment:

    • Plasmapheresis
    • Major surgery (kyphoplasty is not considered major surgery)
    • Radiation therapy (with the exception of radiation therapy to a pathological fracture site to enhance bone healing or to treat post-fracture pain that is to narcotic analgesics)
    • Any anti-myeloma drug therapy
  11. Use of any agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatment
  12. Subjects with conditions requiring chronic or treatment, such as rheumatoid arthritis, multiple sclerosis, and lupus, which likely need additional steroid or immunosuppressive treatments in addition to the study treatment. Includes subjects receiving corticosteroids (> 10 mg/day of prednisone or equivalent) within 3 weeks prior to initiating study treatment
  13. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment will not be eligible to participate in this study
  14. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
  15. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subjects from signing the form
  16. Pregnant or breastfeeding females
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    4 mg Oral POM + 40 mg Oral DEX

    Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle

    Drug: 4 mg Oral POM + 40 mg Oral DEX

  • Experimental
    2 mg Oral POM + 40 mg Oral DEX

    Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle

    Drug: 2 mg Oral POM + 40 mg Oral DEX

Interventions

  • Drug4 mg Oral POM + 40 mg Oral DEX

    Drug page: Dexamethasone

    Also known as: Pomalidomide (POM), Dexamethasone

  • Drug2 mg Oral POM + 40 mg Oral DEX

    Drug page: Dexamethasone

    Also known as: Pomalidomide (POM), Dexamethasone

06

What researchers measure

Primary outcomes

  1. PK-Area under the plasma concentration time curve (AUC)

    PK-Area under the plasma concentration time curve (AUC)

    Time frame: Up to 24 times over 7 months

  2. PK-Time to maximum plasma concentration (Cmax)

    PK-Time to maximum plasma concentration (Cmax)

    Time frame: 24 times over 7 months

  3. PK-Apparent total body clearance (CL/F)

    PK-Apparent total body clearance (CL/F)

    Time frame: 24 times up to 7 months

  4. PK-Renal clearance (CLr)

    PK-Renal clearance (CLr)

    Time frame: 24 times over 7 months

  5. PK-Apparent volume of distribution (V/F)

    PK-Apparent volume of distribution (V/F)

    Time frame: 24 times over 7 months

  6. PK-Effective terminal half-life (T1/2)

    PK-Effective terminal half-life (T1/2)

    Time frame: 24 times over 7 months

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Number of participants with adverse events (AEs)

    Time frame: Up to 5 years

  2. Number of participants alive

    Number of participants alive

    Time frame: Up to 5 years

  3. Time to response

    Time to response

    Time frame: Up to 5 years

  4. Duration of response

    Duration of response

    Time frame: Up to 5 years

07

Study locations

9 sites
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Ingalls Cancer Research Center
    Harvey, Illinois 60426, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 2Y9, Canada
  • L'Hotel Dieu de Quebec
    Quebec, G1R 2J6, Canada
08

References and documents

Publications

  • Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clin Pharmacol. 2017 Nov 8;9:133-145. doi: 10.2147/CPAA.S144606. eCollection 2017. PubMed 29184451 ↗
  • Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3. PubMed 31077258 ↗
  • Matous J, et al. MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI). Presented at: American Society of Clinical Oncology ASCO 2013, May 31-June 4, 2013, Chicago, IL. Abstract No. 8585. JClinOncol 2013;31(suppl 15):8585-8585.
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Aug 2018, 74 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 74 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2012
First posted
Apr 12, 2012
StartActual
Jun 1, 2012
Primary completionActual
Aug 7, 2018
CompletionActual
Aug 7, 2018
Last update
Nov 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01575925
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 12, 2012
Start date
Jun 1, 2012
Primary completion
Aug 7, 2018
Completion
Aug 7, 2018
Last update
Nov 4, 2022

Study contacts

Bristol Myers-Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion